Effect of neoadjuvant therapy on breast cancer biomarker profile

BACKGROUND: Breast cancer clinical management requires the assessment of hormone receptors (estrogen (ER) and progesterone receptor (PR)), human epidermal growth factor receptor 2 (HER2) and cellular proliferation index Ki67, by immunohistochemistry (IHC), in order to choose and guide therapy accord...

Descripción completa

Detalles Bibliográficos
Autores principales: Rey-Vargas, Laura, Mejía-Henao, Juan Carlos, Sanabria-Salas, María Carolina, Serrano-Gomez, Silvia J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368678/
https://www.ncbi.nlm.nih.gov/pubmed/32682413
http://dx.doi.org/10.1186/s12885-020-07179-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368678/
https://www.ncbi.nlm.nih.gov/pubmed/32682413
http://dx.doi.org/10.1186/s12885-020-07179-4

Ejemplares similares